立体定向体部放疗联合或不联合选择性歧化酶模拟物治疗胰腺腺癌:一项适应性、随机、双盲、安慰剂对照的1b/2期试验
这项在美国六家学术中心开展的适应性随机双盲安慰剂对照1b/2期试验纳入42例接受过至少3个月化疗的临界可切除或局部晚期胰腺癌患者,随机接受阿伐索帕森(avasopasem)或安慰剂联合SBRT。阿伐索帕森组50 Gy和55 Gy的晚期EffTox疗效反应分别为16/18(89%)和6/6(100%),安慰剂组分别为3/6(50%)和9/12(75%);贝叶斯模型推荐50 Gy或55 Gy分五次联合阿伐索帕森进一步研究。
要点
- 阿伐索帕森组50 Gy疗效反应16/18(89%),55 Gy为6/6(100%)。
- 安慰剂组50 Gy疗效反应3/6(50%),55 Gy为9/12(75%)。
- 贝叶斯模型推荐50 Gy或55 Gy分五次联合阿伐索帕森进一步研究。
核心结论
- 采用50 Gy或55 Gy分五次的大分割SBRT可考虑用于局部胰腺导管腺癌患者。
- 加用阿伐索帕森可能进一步改善疾病结局。
- 一项更大的2期试验(GRECO-2,NCT04698915)正在进行以验证这些结果。
研究设计与样本
- 在美国六家学术中心开展的适应性、随机、双盲、安慰剂对照1b/2期试验。
- 纳入年龄18岁及以上、临界可切除或局部晚期胰腺癌、接受过至少3个月化疗、ECOG体能状态0-2分的患者。
- 按1:1随机分配至每日阿伐索帕森90 mg或安慰剂静脉给药(SBRT前180分钟内),SBRT剂量为50、55或60 Gy分五次,由贝叶斯90天安全性和有效性估计实时适应性分配。
- 2018年1月25日至2020年4月29日筛查47例,入组42例,随机分配至阿伐索帕森组(n=24)或安慰剂组(n=18);安慰剂组因未达到预设疗效参数而提前终止。
- 主要目标是通过晚期EffTox方法确定阿伐索帕森或安慰剂联合SBRT的最佳剂量,所有分析基于意向性治疗原则。
主要发现
- 阿伐索帕森组晚期EffTox疗效反应:50 Gy为16/18(89%),55 Gy为6/6(100%)。
- 安慰剂组晚期EffTox疗效反应:50 Gy为3/6(50%),55 Gy为9/12(75%)。
- 任何原因严重不良事件:安慰剂组3/18(17%),阿伐索帕森组6/24(25%)。
- 安慰剂组SBRT后90天内3级不良事件为腹痛、急性胆管炎、发热、血乳酸升高和脂肪酶升高(各1例[6%]),无4级事件。
- 阿伐索帕森组SBRT后90天内3-4级不良事件为急性肾损伤、血碱性磷酸酶升高、血肿、结肠炎、胃梗阻、肺部感染、腹腔脓肿、术后心房颤动和导致呼吸衰竭的肺炎(各1例[4%])。
关键数值与推荐
- 贝叶斯模型推荐50 Gy或55 Gy分五次联合阿伐索帕森进一步研究。
- 阿伐索帕森组满足有效性和毒性边界。
- 无治疗相关死亡;阿伐索帕森组报告1例晚期死亡,为十二指肠梗阻情况下脓毒症,发生在研究外治疗后,被认为可能与SBRT相关。
临床怎么用
- 作者认为,采用50 Gy或55 Gy分五次的SBRT可考虑用于局部胰腺导管腺癌患者。
- 作者认为,加用阿伐索帕森可能进一步改善疾病结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stereotactic body radiotherapy (SBRT) has the potential to ablate localised pancreatic ductal adenocarcinoma. Selective dismutase mimetics sensitise tumours while reducing normal tissue toxicity. This trial was designed to establish the efficacy and toxicity afforded by the selective dismutase mimetic avasopasem manganese when combined with ablative SBRT for localised pancreatic ductal adenocarcinoma. METHODS: In this adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial, patients aged 18 years or older with borderline resectable or locally advanced pancreatic cancer who had received at least 3 months of chemotherapy and had an Eastern Cooperative Oncology Group performance status of 0-2 were enrolled at six academic sites in the USA. Eligible patients were randomly assigned (1:1), with block randomisation (block sizes of 6-12) with a maximum of 24 patients per group, to receive daily avasopasem (90 mg) or placebo intravenously directly before (ie, within 180 min) SBRT (50, 55, or 60 Gy in five fractions, adaptively assigned in real time by Bayesian estimates of 90-day safety and efficacy). Patients and physicians were masked to treatment group allocation, but not to SBRT dose. The primary objective was to find the optimal dose of SBRT with avasopasem or placebo as determined by the late onset EffTox method. All analyses were done on an intention-to-treat basis. This study is registered with ClinicalTrials.gov, NCT03340974, and is complete. FINDINGS: Between Jan 25, 2018, and April 29, 2020, 47 patients were screened, of whom 42 were enrolled (median age was 71 years [IQR 63-75], 23 [55%] were male, 19 [45%] were female, 37 [88%] were White, three [7%] were Black, and one [2%] each were unknown or other races) and randomly assigned to avasopasem (n=24) or placebo (n=18); the placebo group was terminated early after failing to meet prespecified efficacy parameters. At data cutoff (June 28, 2021), the avasopasem group satisfied boundaries for both efficacy and toxicity. Late onset EffTox efficacy response was observed in 16 (89%) of 18 patients at 50 Gy and six (100%) of six patients at 55 Gy in the avasopasem group, and was observed in three (50%) of six patients at 50 Gy and nine (75%) of 12 patients at 55 Gy in the placebo group, and the Bayesian model recommended 50 Gy or 55 Gy in five fractions with avasopasem for further study. Serious adverse events of any cause were reported in three (17%) of 18 patients in the placebo group and six (25%) of 24 in the avasopasem group. In the placebo group, grade 3 adverse events within 90 days of SBRT were abdominal pain, acute cholangitis, pyrexia, increased blood lactic acid, and increased lipase (one [6%] each); no grade 4 events occurred. In the avasopasem group, grade 3-4 adverse events within 90 days of SBRT were acute kidney injury, increased blood alkaline phosphatase, haematoma, colitis, gastric obstruction, lung infection, abdominal abscess, post-surgical atrial fibrillation, and pneumonia leading to respiratory failure (one [4%] each).There were no treatment-related deaths but one late death in the avasopasem group due to sepsis in the setting of duodenal obstruction after off-study treatment was reported as potentially related to SBRT. INTERPRETATION: SBRT that uses 50 or 55 Gy in five fractions can be considered for patients with localised pancreatic ductal adenocarcinoma. The addition of avasopasem might further enhance disease outcomes. A larger phase 2 trial (GRECO-2, NCT04698915) is underway to validate these results. FUNDING: Galera Therapeutics.
引用
- Taniguchi CM, Frakes JM, Aguilera TA, et al. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial. Lancet Oncol. 2023. PMID: 38039992. doi:10.1016/S1470-2045(23)00478-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。